Insider Selling: Natera (NASDAQ:NTRA) CEO Sells $909,570.60 in Stock

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 3,580 shares of the company’s stock in a transaction that occurred on Tuesday, July 28th. The stock was sold at an average price of $254.07, for a total transaction of $909,570.60. Following the completion of the sale, the chief executive officer directly owned 102,973 shares of the company’s stock, valued at approximately $26,162,350.11. This represents a 3.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, July 27th, Steven Leonard Chapman sold 2,190 shares of Natera stock. The shares were sold at an average price of $260.49, for a total transaction of $570,473.10.
• On Thursday, June 4th, Steven Leonard Chapman sold 41,124 shares of Natera stock. The stock was sold at an average price of $221.03, for a total value of $9,089,637.72.
• On Friday, May 1st, Steven Leonard Chapman sold 902 shares of Natera stock. The stock was sold at an average price of $206.16, for a total value of $185,956.32.

Natera Price Performance

NTRA opened at $267.76 on Friday. The business has a 50 day moving average price of $246.77 and a two-hundred day moving average price of $222.22. The company has a market capitalization of $38.35 billion, a price-to-earnings ratio of -164.27 and a beta of 1.51. Natera, Inc. has a 1-year low of $131.81 and a 1-year high of $288.04.

Institutional Trading of Natera

Hedge funds have recently made changes to their positions in the stock. Reflection Asset Management acquired a new position in Natera in the 4th quarter valued at approximately $29,000. Elevation Wealth Partners LLC acquired a new stake in shares of Natera during the 2nd quarter valued at $30,000. Palladiem LLC acquired a new stake in shares of Natera during the 4th quarter valued at $31,000. Horizon Investments LLC purchased a new position in shares of Natera during the 3rd quarter valued at $32,000. Finally, International Assets Investment Management LLC grew its holdings in shares of Natera by 132.9% during the 1st quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock valued at $35,000 after acquiring an additional 97 shares in the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on NTRA. William Blair started coverage on Natera in a report on Tuesday, April 14th. They issued an “outperform” rating for the company. Wall Street Zen lowered Natera from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. JPMorgan Chase & Co. boosted their price target on shares of Natera from $260.00 to $265.00 and gave the stock an “overweight” rating in a research report on Friday, May 8th. TD Cowen reissued a “buy” rating on shares of Natera in a report on Wednesday, July 15th. Finally, Sanford C. Bernstein assumed coverage on shares of Natera in a research report on Friday, June 26th. They set an “outperform” rating and a $310.00 price objective for the company. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $267.83.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.